Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No 48; 1979.
- New guidelines to evaluate the response to treatment in solid tumours (RECIST Guidelines).J Natl Cancer Inst. 2000; 92: 205-216
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009; 45: 228-247
- Individual patient data analysis to assess modifications to the RECIST criteria.Eur J Cancer. 2009; 45: 248-260
- Survival predictive accuracy and ROC curves.Biometrics. 2005; 61: 92-105
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.Lancet. 2014; https://doi.org/10.1016/S0140-6736(08)61345-8
- Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.Ann Oncol. 2014; https://doi.org/10.1093/annonc/mdu118
- Facts and controversies in systemic treatment of metastatic breast cancer.Oncologist. 2004; 9: 617-632
- Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?.J Clin Oncol. 2008; 26: 3791-3796
- Recommendations for the assessment of progression in randomised cancer treatment trials.Eur J Cancer. 2009; 45: 281-289